How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

59,638 results for

HIV Test

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

55621. Enhancing Communication and HIV Outcomes

University Study Details Study Description Go to Brief Summary: The goal of this research is to improve communication between the patients with HIV and their health care providers. The overall purpose of doing so is to reduce disparities in medication self-efficacy, adherence to therapy, and HIV viral load suppression. The investigators will conduct a randomized controlled trial to test the effectiveness of a combined provider and patient communication intervention conducted at two separate visits (...) , adherence to therapy, and HIV viral load suppression. We will conduct a randomized controlled trial to test the effectiveness of a combined provider and patient communication intervention conducted at two separate visits compared to usual care in improving the quality of patient-provider communication, patients' medication self-efficacy, patient adherence to therapy, and HIV RNA suppression. The following primary and secondary hypotheses will be addressed. Primary Hypothesis. 1) There will be more

2008 Clinical Trials

55622. Aging & HIV/AIDS Neurocognitive Sequelae and Functional Consequences

serostatus on neuropsychological performance, and this will be evident both cross-sectionally and longitudinally. Specifically, we expect to find that older HIV+ individuals will exhibit greater rates of neuropsychological impairment (using age-corrected test norms) than younger HIV+ persons. Neurocognitive functions subserved by frontal-subcortical systems that are sensitive to the effects of both aging and HIV infection (learning, motor and psychomotor speed, executive function (...) have documented presence or absence of HIV infection (depending on their group assignment), based on serologic testing for HIV antibody (screening ELISA, confirmed by Western blot if positive). The documentation of HIV status will be obtained once informed consent has been established. Exclusion Criteria: CNS infection other than HIV (no opportunistic CNS disease) CNS neoplasm, neurosyphilis traumatic brain injury with loss of consciousness greater than 30 minutes current diagnosis of seizure

2008 Clinical Trials

55623. Pharmacokinetics of Rifabutin Combined With Antiretroviral Therapy in Patients With TB/HIV Co-infection in Vietnam

Additional relevant MeSH terms: Layout table for MeSH terms Infection Communicable Diseases HIV Infections Acquired Immunodeficiency Syndrome Tuberculosis Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Immunologic Deficiency Syndromes Immune System Diseases Slow Virus Diseases Mycobacterium Infections Actinomycetales Infections Gram-Positive Bacterial Infections Bacterial Infections Ritonavir Lopinavir (...) doses that will be further tested in a larger phase III trial comparing safety, tolerability and efficacy of RBT and RMP regimens. Condition or disease Intervention/treatment Phase HIV Infections Tuberculosis Drug: rifabutin in combination with lopinavir boosted by ritonavir - dosing schedule 1 Drug: rifabutin in combination with lopinavir boosted by ritonavir - dosing schedule 2 Phase 2 Detailed Description: Patients will be offered to participated in the study when they start TB treatment. All

2008 Clinical Trials

55624. Metabolic Impact Assessment of Tenofovir Disoproxil Fumarate on Non-HIV-1 Infected Healthy Adult Male Volunteers

provided by Gilead Sciences: HIV-1 tenofovir DF Additional relevant MeSH terms: Layout table for MeSH terms HIV Infections Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Immunologic Deficiency Syndromes Immune System Diseases Tenofovir Antiviral Agents Anti-Infective Agents Reverse Transcriptase Inhibitors Nucleic Acid Synthesis Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological (...) Metabolic Impact Assessment of Tenofovir Disoproxil Fumarate on Non-HIV-1 Infected Healthy Adult Male Volunteers Metabolic Impact Assessment of Tenofovir Disoproxil Fumarate on Non-HIV-1 Infected Healthy Adult Male Volunteers - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved

2008 Clinical Trials

55625. Cognitive Behavioral Stress Management for HIV+ Drug Abusers

information Ages Eligible for Study: 18 Years to 60 Years (Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria >18, but <60 years of age fluency in spoken English which is required to complete assessments and to participate in the intervention groups; acknowledgement of HIV seropositivity and willingness to be tested to confirm this serostatus; currently not cognitively impaired since cognitive impairment may compromise the ability to comprehend and participate in the assessment (...) Cognitive Behavioral Stress Management for HIV+ Drug Abusers Cognitive Behavioral Stress Management for HIV+ Drug Abusers - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Cognitive Behavioral Stress

2008 Clinical Trials

55626. Effectiveness of a Community-level HIV/STD Prevention Intervention in Promoting Safer Sexual Behaviors in High-risk Populations

groups operating within the community and to identify and recruit the opinion leaders who are influential in these groups. Also, an epidemiological study will be conducted to collect information on sexual behaviors and HIV/STD rates. A cohort of members from participating communities will first undergo baseline assessments that will include a survey about general health and knowledge of HIV/STDs and a biological sampling for HIV/STD testing. Participating communities will then be assigned randomly (...) sessions over the next 2 years to reinforce and support continued conversation efforts. Communities assigned to receive the HIV/STD educational materials will receive informational materials on HIV/STDs to provide to community members and will provide treatment or treatment referral for people with nonviral STDs. All participants in the baseline cohort will be asked to repeat the baseline testing 1 and 2 years later. Participants who are not able to visit a clinic for testing will be contacted by phone

2008 Clinical Trials

55627. Phase I Study of HIV Adenoviral Vector Vaccine in Healthy Subjects Using Needle or Biojector Injection

as evidenced by a negative FDA-approved HIV diagnostic blood test if enrolling into Group 1 or negative HIV polymerase chain reaction (PCR) test if enrolling into Group 2 Negative hepatitis B surface antigen (HbsAg). Negative anti-HCV (hepatitis C virus antibody) and negative HCV PCR. Female-Specific Criteria: Negative beta-HCG (human chorionic gonadotropin) pregnancy test (urine or serum) on day of enrollment for women presumed to be of reproductive potential. A female participant must meet any (...) , is made using an adenovirus that has been modified to contain DNA that codes for three HIV proteins. It cannot cause HIV or adenoviral infections. Healthy volunteers who are not infected with the HIV virus may be eligible for this study. Subjects are recruited for two study groups: Group 1 comprises volunteers who are 18 to 50 years old and have never received an HIV vaccine and Group 2 comprises volunteers who are 18 to 55 years old and participated in a prior study in which they received at least

2008 Clinical Trials

55628. Directly Administered Antiretroviral Therapy (DAART) Among HIV-1infected Injecting Drug Users (IDUs) in Chennai, India

the DSM-IV criteria (see Appendix) Urine screening must test positive for presence of opioids Documented evidence of HIV infection (double ELISA: Murex HIV-1.2.O, Abbott Murex, UK and Vironostika® HIV Uni-form II Ag/Ab, Biomérieux, The Netherlands) Be ART naïve (by self-report) If female of childbearing potential (all of the following) Have a negative urine pregnancy test Be willing to use barrier based or oral contraceptive for the duration of the study if sexually active. Satisfy Indian National (...) Last Update Posted: April 15, 2015 Last Verified: March 2009 Additional relevant MeSH terms: Layout table for MeSH terms HIV Infections Heroin Dependence Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Immunologic Deficiency Syndromes Immune System Diseases Opioid-Related Disorders Substance-Related Disorders Chemically-Induced Disorders Mental Disorders Anti-Retroviral Agents Antiviral Agents Anti

2008 Clinical Trials

55629. Impact of an HPV Vaccine in HIV-Infected Young Women

Impact of an HPV Vaccine in HIV-Infected Young Women Impact of a Human Papilloma Virus (HPV) Vaccine in HIV-Infected Young Women - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Impact of a Human Papilloma (...) Carolina, Chapel Hill ClinicalTrials.gov Identifier: Other Study ID Numbers: ATN 064 First Posted: July 4, 2008 Results First Posted: May 22, 2017 Last Update Posted: July 2, 2017 Last Verified: April 2017 Keywords provided by University of North Carolina, Chapel Hill: Highly-active antiretroviral therapy Human papillomavirus HPV vaccine Additional relevant MeSH terms: Layout table for MeSH terms HIV Infections Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases Sexually

2008 Clinical Trials

55630. HIV-1 Viral Dynamics in Subjects Initiating Raltegravir Therapy

drawing Detailed Description: This pilot study will closely examine the viral dynamics of both HIV-1 RNA and DNA in treatment-experienced subjects initiating raltegravir. The data derived from this study will further elucidate the effects of antiviral therapy on viral decay and help refine current viral dynamics models. In addition, results of this study will generate hypotheses for further testing regarding the mechanisms of action of integrase inhibitor therapy in salvage regimens. Lastly (...) in the intracellular levels of HIV-1 proviral DNA and LTR circles during raltegravir therapy. [ Time Frame: 24 weeks ] 3. Correlate changes in the intracellular DNA compartments with first- and second-phase plasma HIV-1 RNA clearance rates. [ Time Frame: 24 weeks ] Biospecimen Retention: Samples With DNA Peripheral blood mononuclear cells will be tested for HIV-1 DNA levels. The cell pellets obtained from each of the samples will be tested for 1) total HIV-1 DNA and 2-LTR circles using real-time quantitative PCR

2008 Clinical Trials

55631. Enema Use and Acceptability in HIV Negative Men Who Have Sex With Men

Statement: Plan to Share IPD: No Keywords provided by Johns Hopkins University: HIV prevention MSM Enema HIV Seronegativity Additional relevant MeSH terms: Layout table for MeSH terms HIV Infections Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Immunologic Deficiency Syndromes Immune System Diseases Plasma-lyte 148 Ophthalmic Solutions Pharmaceutical Solutions (...) Enema Use and Acceptability in HIV Negative Men Who Have Sex With Men Enema Use and Acceptability in HIV Negative Men Who Have Sex With Men - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Enema Use

2008 Clinical Trials

55632. Safety and Immune Response to a Recombinant Adenovirus HIV-1 Vaccine in Healthy Adults

Eligible for Study: 18 Years to 50 Years (Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: Yes Criteria Inclusion Criteria: Good general health Normal hematological, hepatic and renal functions Demonstrated understanding of study Willing to receive HIV test results HIV-1 and -2 uninfected Hepatitis B surface antigen negative Anti-hepatitis C virus (anti-HCV) negative antibody or negative HCV PCR if anti-HCV is positive Adequate contraception. For more information on this criterion can (...) and physical exams will occur at all visits. At most visits, blood, urine, and oral swab collection will occur. Samples collected will be stored for future testing. HIV testing and pregnancy testing will occur at select visits. At Years 2, 3, 4, and 5, participants will be followed-up by telephone, e-mail, or study visit to collect vital status, and information about any development of significant disability or incapacity, hospitalizations, or congenital anomalies. At these follow-up visits, blood

2008 Clinical Trials

55633. Detecting Anal and Genital Human Papillomavirus Infection and Squamous Intraepithelial Lesions in HIV-Positive Patients Enrolled in AIDS Cancer Clinical Trials

are study participants on interventional AMC protocols for diseases other than HPV-associated neoplasia with an accrual goal of 15 patients or more. Criteria DISEASE CHARACTERISTICS: Serologic documentation of HIV infection by any FDA-approved tests Enrolled in an AIDS Malignancy Clinical Trials Consortium (AMC) clinical trial of any new or existing pharmacotherapeutic agent for treatment of disease other than human papillomavirus (HPV)-associated neoplasia AMC study must have an accrual target of > 15 (...) Detecting Anal and Genital Human Papillomavirus Infection and Squamous Intraepithelial Lesions in HIV-Positive Patients Enrolled in AIDS Cancer Clinical Trials Detecting Anal and Genital Human Papillomavirus Infection and Squamous Intraepithelial Lesions in HIV-Positive Patients Enrolled in AIDS Cancer Clinical Trials - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study

2008 Clinical Trials

55634. Effectiveness of Community-Level Behavioral and Biomedical Interventions for Reducing HIV/STIs in Men in Peru

to any treatment and will include an interview, counseling, and HIV/STI testing. The interview will involve questions about health and community, including topics such as sexual activities, views on health problems, use of alcohol and drugs, use of health care services, and attitudes about people with HIV or AIDS. Counselors will then provide information about contracting and preventing HIV/STIs and will ask questions about STI symptoms. Finally, HIV/STI testing will be conducted and throat and anal (...) swabs will be collected. Two weeks after the initial evaluation, MSM will receive their test results, and if positive for HIV or any STIs, they will receive appropriate referrals, services, and treatments. They will also receive the specific treatment to which their community was assigned and will be asked additional questions concerning the treatment of their partners, if applicable. The remaining evaluations, which will repeat assessments from the initial evaluation, will occur at months 9 and 18

2008 Clinical Trials

55635. HIV Vertical Transmission in Vietnam

Mother willing to enroll to study and their child For mother: Their HIV status was diagnosed by at least one quick test and two different ELISA serological tests. For their child: the child had tested HIV at list 3 time one at birth, one at 12 or 18 months and one in between. Exclusion Criteria: The child had less than 3 time to test. Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff (...) Posted: April 30, 2008 Last Verified: April 2008 Keywords provided by National Institute of Hygiene and Epidemiology, Vietnam: Mother to child transmission of HIV HIV infected children Additional relevant MeSH terms: Layout table for MeSH terms HIV Infections Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Immunologic Deficiency Syndromes Immune System Diseases

2008 Clinical Trials

55636. Trial Comparing Two Strategies of Vaccination Against Hepatitis B in HIV-infected Patients Non Responding to Primary Immunization (B-BOOST)

Description Go to Brief Summary: HIV infected patients exposed to Hepatitis B virus are more susceptible to develop a chronic and severe liver disease, with a major risk of cirrhosis and liver cancer. However, immune response to standard Hepatitis B vaccination is decreased in HIV-infected patients, compared to non HIV-infected individuals, and, in case of response, its durability has to be carefully followed up. This study compares the efficacy of two strategies of revaccination in HIV-infected patients (...) and S24), Versus Standard Dose Vaccination (20 µg at S0, S4 and S24), Against Hepatitis B Virus in HIV-1-infected Patients Without Any Previous Immune Response After Primary Immunization Plus One Single Boost Study Start Date : May 2008 Actual Primary Completion Date : December 2011 Actual Study Completion Date : February 2013 Resource links provided by the National Library of Medicine related topics: Arms and Interventions Go to Arm Intervention/treatment Active Comparator: A GenHevac-B 20 microgram

2008 Clinical Trials

55637. HIV Treatment-Readiness Measure (HTRM) Validation

properties of the HTRM and establish its test-retest reliability over a two week period. If the HTRM is found to be reliable, a subsequent study will examine its predictive validity. Condition or disease HIV Infections Study Design Go to Layout table for study information Study Type : Observational Actual Enrollment : 200 participants Observational Model: Cohort Time Perspective: Prospective Official Title: Validation of the HIV Treatment Readiness Measure (HTRM) Study Start Date : May 2008 Actual (...) , 2008 Last Update Posted: February 28, 2017 Last Verified: February 2016 Keywords provided by University of North Carolina, Chapel Hill: HIV Treatment Readiness Measure (HTRM) Highly Active Antiretroviral Treatment (HAART) Adherence Treatment readiness HIV Additional relevant MeSH terms: Layout table for MeSH terms HIV Infections Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Immunologic Deficiency

2008 Clinical Trials

55638. Pilot Trial of a Synbiotic in HIV+ Patients

by University of California, Davis: HIV synbiotic probiotic immune activation blood CD4 count bacterial translocation Human Immunodeficiency Virus Additional relevant MeSH terms: Layout table for MeSH terms HIV Infections Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Immunologic Deficiency Syndromes Immune System Diseases (...) is to test the hypothesis that daily ingestion of a 'synbiotic' for 4 weeks will improve intestinal function, ease immune system overactivation, and increase blood CD4 count in HIV-infected individuals. A 'Synbiotic' is a mixture of probiotic bacteria and dietary fiber. Condition or disease Intervention/treatment Phase HIV Infection Dietary Supplement: Synbiotic 2000 Dietary Supplement: Placebo Not Applicable Detailed Description: RATIONALE. HIV infection results in alterations to the intestinal tract

2008 Clinical Trials

55639. Peroral Supplemental Nutrition in End-stage Renal Disease With and Without HIV Comorbidity

University Hospital Collaborator: Pfrimmer Nutricia GmbH, Erlangen , Germany Information provided by: Johann Wolfgang Goethe University Hospital Study Details Study Description Go to Brief Summary: End-stage renal disease is often accompanied by malnutrition due to less appetite, metabolic changes or both. Human immunodeficiency virus-infection may exacerbate the state of malnutrition. In a pilot study, we recruit both HIV invected and non-infected patients on hemodialysis. Non-HIV patients (...) changes, malnutrition, or both appear to be the underlying problems. In fact, lean body mass per body weight better predicts prognosis than creatinin based models (NDT, 2004.19:1182). In addition, comorbidity such as HIV infection may exacerbate cachexia found in ESRD. Whether or not daily supplemental, high-caloric nutrition in ESRD corrects a catabolic state in ESRD is unclear. Hypothesis to be tested: Daily supplemental high-caloric nutrition beneficially affects cytokine stimulation (TNF alpha, IL

2008 Clinical Trials

55640. Vicriviroc (SCH 417690) Treatment Protocol in HIV-Infected Subjects: A Rollover Study for ACTG Protocol A5211 (Study P04100AM4)(COMPLETED)

to Primary Outcome Measures : Long-term safety and tolerability, including CD4/CD8 count, HIV RNA, vicriviroc drug-susceptibility testing, SAEs, new infections, AIDS-defining events, and changes in coreceptor tropism of HIV isolates. [ Time Frame: Throughout the study ] Eligibility Criteria Go to Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study (...) Vicriviroc (SCH 417690) Treatment Protocol in HIV-Infected Subjects: A Rollover Study for ACTG Protocol A5211 (Study P04100AM4)(COMPLETED) Vicriviroc (SCH 417690) Treatment Protocol in HIV-Infected Subjects: A Rollover Study for ACTG Protocol A5211 (Study P04100AM4)(COMPLETED) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study

2008 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>